Clinical Trials at University of Rochester
As of August 2026, 150 paid clinical trials are recruiting at University of Rochester, located at 601 ELMWOOD AVE, BOX 684, ROCHESTER, NY 14642-0002, phone (585) 275-2100 in Rochester, New York. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Breast Cancer and Obesity. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
150 clinical trials at University of Rochester
·Clear filters·A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Nectero EAST System Clinical Study
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval Study
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Remote Assessments and Genetic Determinants of Myotonic Dystrophy
A Pilot Randomized Controlled Trial of a Social Network Intervention
Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Common conditions studied in Rochester
- Acute Myeloid Leukemia (12 active studies)
- Breast Cancer (10 active studies)
- Obesity (9 active studies)
- Overweight (7 active studies)
- Cancer (6 active studies)
- Prostate Cancer (6 active studies)
Leading research sponsors in Rochester
- University of Rochester
- National Cancer Institute (NCI)
- Eli Lilly and Company
- SWOG Cancer Research Network
- Children's Oncology Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Rochester?
There are approximately 475 recruiting clinical trials in Rochester, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Rochester pay participants?
Most recruiting trials in Rochester compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Rochester?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Rochester?
The most common conditions under active study in Rochester include Acute Myeloid Leukemia (12), Breast Cancer (10), Obesity (9), Overweight (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Rochester?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Rochester on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Rochester?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Rochester?
Recruiting research sites in Rochester include University of Rochester, University of Rochester Medical Center, Rochester Clinical Research, LLC, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Rochester right now?
The largest active categories in Rochester are Cancer & tumors (177), Neurology & pain (32), Cardiovascular (24). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Rochester?
University of Rochester is located at 601 ELMWOOD AVE, BOX 684, ROCHESTER, NY 14642-0002. Use the Google Maps link in the intro above to get directions.
How do I contact University of Rochester?
You can reach University of Rochester by phone at (585) 275-2100. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.